Metabolic syndrome and dyslipidemia in xanthelasma palpebrarum and associated risk-2 factors-A case-control study.
Xanthelasma palpebrarum
dyslipidemia
metabolic syndrome
risk factors
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
revised:
11
08
2022
received:
25
03
2022
accepted:
01
09
2022
pubmed:
4
9
2022
medline:
6
1
2023
entrez:
3
9
2022
Statut:
ppublish
Résumé
Xanthelasma palpebrarum (XP) primarily causes cosmetic disfigurement. However, systemic associations like metabolic syndrome (MetS) and dyslipidemia need consideration. Determining the prevalence of MetS and dyslipidemia in XP patients and explore risk factors. Our case-control study included 106 XP patients(cases) and 106 age-and-sex matched healthy controls. All subjects underwent detailed history taking, physical examination, and biochemical investigations. MetS and obesity were diagnosed by NCEP-ATP III criteria and modified BMI classification for Asian-Indians, respectively. The odds ratio (OR) and 95% CI for XP patients vs. non-XP controls were 1.6 (95% CI 0.8-3.2, p = 0.1) for MetS, 1.4 (95% CI 0.6-3.1, p = 0.4) for dyslipidemia and 0.2 (95% CI 0.07-0.4, p < 0.0001) for overweight/obesity. Extensive disease, DM, and low serum HDL-C were significantly associated with MetS in XP patients (vs. controls). Normal waist circumference (AOR 21.3, 95% CI 3.5-127.6, p = 0.0008), normal blood glucose (AOR 21.4, 95% CI 3.1-145.1, p = 0.002), and normal blood pressure (AOR 22.3, 95% CI 3.9-124.9, p = 0.0004) significantly reduced the risk of MetS, while bilateral ocular involvement (AOR 4.3, 95% CI 1.1-18.7, p = 0.04) significantly increased the risk of dyslipidemia in XP patients. Xanthelasma palpebrarum patients are more prone to develop MetS and dyslipidemia and need evaluation, despite being a primarily cosmetic concern. Extensive disease and bilateral ocular involvement are significant risk factors. Adequate counseling and healthy life-style measures are crucial to minimize systemic complications.
Sections du résumé
BACKGROUND
BACKGROUND
Xanthelasma palpebrarum (XP) primarily causes cosmetic disfigurement. However, systemic associations like metabolic syndrome (MetS) and dyslipidemia need consideration.
OBJECTIVE
OBJECTIVE
Determining the prevalence of MetS and dyslipidemia in XP patients and explore risk factors.
METHODS
METHODS
Our case-control study included 106 XP patients(cases) and 106 age-and-sex matched healthy controls. All subjects underwent detailed history taking, physical examination, and biochemical investigations. MetS and obesity were diagnosed by NCEP-ATP III criteria and modified BMI classification for Asian-Indians, respectively.
RESULTS
RESULTS
The odds ratio (OR) and 95% CI for XP patients vs. non-XP controls were 1.6 (95% CI 0.8-3.2, p = 0.1) for MetS, 1.4 (95% CI 0.6-3.1, p = 0.4) for dyslipidemia and 0.2 (95% CI 0.07-0.4, p < 0.0001) for overweight/obesity. Extensive disease, DM, and low serum HDL-C were significantly associated with MetS in XP patients (vs. controls). Normal waist circumference (AOR 21.3, 95% CI 3.5-127.6, p = 0.0008), normal blood glucose (AOR 21.4, 95% CI 3.1-145.1, p = 0.002), and normal blood pressure (AOR 22.3, 95% CI 3.9-124.9, p = 0.0004) significantly reduced the risk of MetS, while bilateral ocular involvement (AOR 4.3, 95% CI 1.1-18.7, p = 0.04) significantly increased the risk of dyslipidemia in XP patients.
CONCLUSION
CONCLUSIONS
Xanthelasma palpebrarum patients are more prone to develop MetS and dyslipidemia and need evaluation, despite being a primarily cosmetic concern. Extensive disease and bilateral ocular involvement are significant risk factors. Adequate counseling and healthy life-style measures are crucial to minimize systemic complications.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7018-7024Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Nair PA, Singhal R. Xanthelasma palpebrarum - a brief review. Clin Cosmet Investig Dermatol. 2017;11:1-5.
Gondane S, Meherda A, Kothiwala R. To study the prevalence of metabolic syndrome and dyslipidemia in patients of xanthelasma palpebrarum at a tertiary care hospital. Ind J Clin Pract. 2020;31:338-342.
Jain A, Goyal P, Nigam PK, Gurbaksh H, Sharma RC. Xanthelasma Palpebrarum-clinical and biochemical profile in a tertiary care hospital of Delhi. Indian J Clin Biochem. 2007;22:151-153.
Agarwal K, Das S. Metabolic syndrome-The underbelly of dermatology. Gulf J Dermatol and Venerol. 2019;26:1-10.
Podder I, Agarwal K, Anurag A. Metabolic status, obesity, and quality of life in patients with acne vulgaris: a cross-sectional case-control study. Indian J Dermatol. 2021;66:223.
Shenoy C, Shenoy MM, Rao GK. Dyslipidemia in dermatological disorders. North Am J Med Sci. 2015;7:421-428.
Pandhi D, Gupta P, Singal A, Tondon A, Sharma S, Madhu SV. Xanthelasmapalpebrarum: a marker of premature atherosclerosis (risk of atherosclerosis in xanthelasma). Postgrad Med J. 2012;88:198-204.
Aziz N, Kallur SD, Nirmalan PK. Implications of the revised consensus body mass indices for Asian Indians on clinical obstetric practice. J Clin Diagn Res. 2014;8:OC01.
Roberts WC. The metabolic syndrome. Am J Cardiol. 2004;93(2):274.
Kavoussi H, Ebrahimi A, Rezaei M, Ramezani M, Najafi B, Kavoussi R. Serum lipid profile and clinical characteristics of patients with xanthelasma palpebrarum. An Bras Dermatol. 2016;91:468-471.
Chhetri MK, Chowdhury ND, De B. Xanthelasma palpebrarum: an analysis of 141 cases. J Assoc Physicians India. 1967;15:405-412.
Dey A, Aggarwal R, Dwivedi S. Cardiovascular profile of xanthelasma palpebrarum. Biomed Res Int. 2013;2013:932863.
Wang KY, Hsu KC, Liu WC, Yang KC, Lee WC. Relationship between xanthelasma palpebrarumand hyperlipidemia. Ann Plast Surg. 2018;80:84-86.
Sharma P, Patgiri D, Sharma G, Pathak MS. Serum lipid profile in Xanthelasma palpebrum. Indian J Basic Appl Med Res. 2013;7:732-737.
Urbano FL. Ocular sign of hyperlipidemia. Hosp Physician. 2001;37:51-59.
Ahmki S, Begum K, Rahman K, et al. Association of Xanthelasma palpebrarum (XP) with cardiovascular disease (CVD) risk factors. Asian J Bio Res. 2019;5:324-329.
Li X, Wang A, Wang J, et al. Association between high-densitylipoprotein-cholesterol levels and the prevalence of asymptomatic intracranial arterial stenosis. Sci Rep. 2017;7:573.
Kim YG, Oh JW, Lee KC, Yoon SH. Clinical association between serum cholesterol level and the size of xanthelasma palpebrarum. Arch Craniofac Surg. 2022;23(2):71-76.